Other headlinesGMI builds clinical war ches
Toshiba boosts Infinix image quality
Toshiba America Medical Systems unveiled Sept 21 a low-contrast capability for Infinix-i systems that feature mid- and large-size flat panel detectors. The new capability was a feature of its exhibit at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco. The Low-Contrast Imaging (LCI) technology enables better visualization of soft tissue in the angio suite, according to the company, delivering CT-like images of the liver, brain, and cerebral ventricles. LCI may be used to improve diagnosis, as well as to confirm appropriate endpoints during interventional procedures, such as aortic stent-grafting, the company said. The Infinix-i line features a five-axis C-arm that covers patients head-to-toe and fingertip-to-fingertip.
GMI builds clinical war chest
Gamma Medica-Ideas has raised $24 million to support efforts to grow its presence in the clinical marketplace with digital SPECT, PET, and CT products. Psilos Group, a healthcare venture capital firm, and Capital Resource Partners, a provider of hybrid growth financing, contributed $14 million in equity capital. Capital Resource Partners also provided $5 million in mezzanine debt. The technology lending group at Bridge Bank rounded out the financing with a $5 million revolving line of credit. Historically, GMI has served the pre-clinical imaging market, where the need for increased productivity is driving demand for medical research and drug discovery applications. Its small animal imaging products are distributed in Japan by SII NanoTechnology and elsewhere by GE Healthcare. With this financing, GMI plans to leverage its digital imaging technology platform into clinical imaging markets, where the company will promote its products as the means to improved diagnosis at lower costs. GMI’s initial product, LumaGEM, is focused on improving the diagnosis of cancers in women with dense breast tissue.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.